MedTrace Logo

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

NCT01080768 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2011-12-26

Study results available
· View outcomes & findings →

Summary

The purpose of the present study was to evaluate the addition of aliskiren, to amlodipine can attenuate ankle edema formation in hypertensive patients.

Conditions

Interventions

DRUG

Aliskiren/amlodipine

Aliskiren/amlodipine 150/5 mg/day

DRUG

Amlodipine

Amlodipine 5 mg/day.

DRUG

Placebo to Aliskiren/amlodipine

Placebo to Aliskiren/amlodipine 150/10 mg/day

DRUG

Placebo to Amlodipine

Placebo to Amlodipine 5 mg/day

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080768 on ClinicalTrials.gov